- Home
- » Tags
- » Ramucirumab
Top View
- Ramucirumab: a New Therapy for Advanced Gastric Cancer
- Ramucirumab) Injection, for Intravenous Use Weeks Following a Major Surgical Procedure and Until Adequate Initial U.S
- IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
- Progress in EGFR-Mutant NSCLC
- REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors Kyriakos P
- (INN) for Biological and Biotechnological Substances
- Therapeutic Targeting of the Angiopoietin–TIE Pathway
- FDA Briefing Document Oncologic Drugs Advisory Committee Meeting
- Gastric Cancers
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- Ramucirumab As a Second-Line Treatment for Locally Advanced Or Metastatic Urothelial Carcinoma: a Meta- Analysis of Randomized Clinical Trials †
- Trastuzumab Emtansine (Kadcyla) for Patients with HER2 Positive Locally Advanced Or Metastatic Relapsed Gastric Cancers
- How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?
- Billing and Coding Guide INDICATIONS
- PDCO Minutes of the 15-18 August 2017 Meeting
- Newly Diagnosed Glioblastoma
- Strategic Collaboration in Oncology Trastuzumab Deruxtecan (DS-8201)
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
- DAIICHI SANKYO CO., LTD. Sunao Manabe President and CEO June 8, 2021
- Ramucirumab (Cyramza) National Drug Monograph June 2015 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives
- An Overview of the Current Status of Engineered Therapeutic Monoclonal Antibodies
- Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care
- CYRAMZA Either As a Single Agent Or CYRAMZA Safely and Effectively
- Cross Discipline Team Leader Review
- Clinical Development Program for More Than 50 Years
- Lilly Highlights Advancements in Its Oncology Portfolio with New Data at ESMO 2016
- Ramucirumab (Cyramza®) Approved By: UM Pharmacy Subcommittee
- Review Report May 17, 2016 Pharmaceuticals and Medical
- USP Medicare Model Guidelines V7.0 (With Example Part D Drugs)
- Lilly and Merck Expand Immuno-Oncology Collaboration
- Participating Provider Precertification List Effective January 14, 2016
- ALX Oncology November 16, 2020 KOL Presentation
- Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric Or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1A/B JVDF Trial
- Second-Line Treatment of Advanced Gastric Cancer: Current Options and Future Perspectives
- Lartruvo, INN-Olaratumab
- Safety of Ramucirumab Regimen Without H1-Antihistamine
- Ramucirumab LY3009806 IMC-1121B
- (INN) for Biological and Biotechnological Substances
- Global Oncology
- 761038Orig1s000
- 125547Orig1s000
- Vectibix® (Panitumumab)
- A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy
- Ramucirumab: Successfully Targeting Angiogenesis in Gastric Cancer
- DRUG NAME: Ramucirumab
- Algorithm for the Treatment of Advanced Or Metastatic Squamous Non-Small-Cell Lung Cancer: an Evidence-Based Overview
- Continuation of Trastuzumab Beyond Disease Progression in HER2-Positive Metastatic Gastric Cancer: the MD Anderson Experience
- Has Approved Aloxi® (Palonosetron HCI) Cyramza™ (Ramucirumab)For
- Ramucirumab Efficacy in First-Line Gastric and Esophageal Cancer Treatment
- Assessment of the Evolution of Cancer Treatment Therapies
- Gastric and Esophageal Cancers: Guidelines Updates
- Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III
- Ramucirumab in the Second-Line Treatment of Metastatic Colorectal Cancer: a Narrative Review of Literature from Clinical Trials
- Publication Agenda CHMP 07-10 December 2020
- A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective Against Triple Negative Breast Cancer Via Multiple Mechanisms
- New Therapeutic Approaches to Bladder Cancer Daniel P
- Report on the Deliberation Results May 16, 2016 Evaluation And
- WO 2017/189679 Al 02 November 2017 (02.11.2017) W !P O PCT
- Cyramza Utilization Management Medical Policy • Cyramza® (Ramucirumab Intravenous Infusion – Eli Lilly)